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Abstract. The article contains the analysis of medical and biological publications from the global 
database created by the National Centre for Biology Information (NCBI), an intramural 
biotechnological division of the US National Library of Medicine. The authors have analyzed 
publications of the recent ten years. Major results of study of erythropoietins and their 
recombinant analogues have been generalized and systematized. There has been revealed the 
significant potential of the preparations of this group to be studied and used. Major advantages 
and drawbacks of erythropoietins and their recombinant analogues have been described. It has 
been pointed out that a great variety of erythropoietins and darbepoetins speaks to the fact that 
there is lack of “universe” erythropoietin meeting all the requirements. Genetically modified 
erythropoietin having both – pharmacokinetics convenient for clinical application and all 
properties of the natural analogue – is considered to be the most successful darbepoetin. This 
property has been resulted from the fact that comparing to standard erythropoietin darbepoetin 
has bigger molecular weight due to introduction of 2 complementary sites of glycosylation. This, 
in turn, results in the increase of half-life period and, consequently, decreases application 
frequency of the preparation that makes it more convenient to use comparing to erythropoietin. 
Application of erythropoietin and its derivatives in stroke therapy in experimental animal models 
undoubtedly has positive impact on the reduction of the infarction size and dynamics of recovery 
of neurological status. Results of the analysis demonstrate that the studied preparations are more 
effective in the early period following stroke than being applied in the later hours. However, there 
has been revealed some insufficient knowledge in treatment of brain ischemic lesions and 
ischemic heart disease.  
Key words: erythropoietin, darbepoetin, stroke. 
 
Introduction. Medicine is considered to be 
actively developing science judging from the 
dynamics of information accumulation.15% of 
medical database is renewed every year. This means 
that in the period less than 7 years practically all 
medical paradigms are being revised. The fact should 
be taken into consideration that medical practitioners 
are being trained for 7-8 years and 2-3 years are 
necessary to revise, write and publish learning 
material. Thus, it appears that young health care 
workers start their practice having knowingly 
obsolete knowledge and to be updated a young 
specialist should spend a lot of time studying 
incoming information. Needless to say, young 
medical workers have a lot of difficulties learning all 
new publications appearing during a year. Thus, 
currently publication of review articles is essential to 
guide in the actual information flow of periodic.  
The objective of this article is to summarize the 
most interesting experimental models and research 
results carried out for the last ten years to search new 
preparations on the basis of darbepoetin for the 
ischemic stroke therapy.  
Materials and methods. To analyze research 
articles the authors used global database of medical and 
biological publications in English language created by 
the National Centre for Biotechnology Information 
(NCBI), an intramural biotechnological division of the 
US National Library of Medicine, which houses the 
most updated and complete articles on the subject of the 
review. There have been collected 2386 publications 
regarding erythropoietin in the text database on 
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biotechnological information (NCBI) for the last ten 
years, almost a thousand more – regarding its 
recombinant analogue darbepoetin. This statistical fact 
alone supports essential medical significance of 
erythropoietins. Notable interest has been registered in 
the study of neuroprotective effect of erythropoietin and 
its analogues for the recent decades [1]. For more 
suitable analysis the authors of the article have designed 
a table, where methods and results of the investigational 
trials are presented concisely and comprehensibly. The 
Table contains research results of 11 studies 
demonstrating various models of brain damages, 
describes in details ways and methods of introduction of 
the investigated preparations and shows data that prove 
efficiency of application of erythropoietin, as well as its 
analogues, in various forms [2]. 
The advantage of application of erythropoietin 
and its derivatives in the therapy of brain damages of 
diverse genesis is considered to be the fact that 
erythropoietin is a cytokine, which is produced inside 
the body and its production is genetically determined. 
A stimulus for erythropoietin synthesis is reported to 
be decrease of the oxygen content in cells resulting in 
the formation of hypoxia- inducible factor-1(HIF-1) 
followed by mRNA and, actually, erythropoietin 
production [3, 4]. An erythropoietin gene contains a 
complementary HIF-1a region; binding to it triggers 
transcription of mRNA erythropoietin. HIF-1 
expression is defined in cells just in 30 minutes after 
hypoxia has started. The major application point of 
erythropoietin action is granulocytic-monocytic-
megakaryocytic-erythrocytic burst and colony 
forming units that have specific receptors. 
Erythropoietin is responsible for proliferation, 
differentiation and inhibition of apoptosis in these 
cells; decreased apoptosis of bone marrow erythroid 
progenitor cells being the major effect of 
erythropoietin in these conditions. Erythropoietin 
takes an effect through surface receptors that are 
amounted no more than 1000 per one cell. Receptors 
to erythropoietin are found in the cells of the nerve 
tissue, ovaries and testes, uterus, in the vascular 
smooth muscle cells, cardiomyocytes, 
endotheliocytes, lung and renal tubules epithelium. 
These cells are not only able to express 
erythropoietin receptors; some of them are capable to 
synthesize erythropoietin itself. Presence of these 
potencies allows assuming that erythropoietin 
performs some functions different from 
hematopoietic function [5]. Due to this fact, a number 
of investigational trials on animals, which support 
positive effect of erythropoietin and its analogues on 
the recovery of the brain functions after damages of 
various etiologies, have increased. The objective of 
this article is to review the most interesting 
experimental models and results of the research 
studies carried out for the last ten years.  
 
Figure 1. Amino acid sequence of the darbepoetin alpha 
molecule (replacement of 5 amino acids in polypeptide 
chain by the method of site-directed mutagenesis allowed 
creating 5 sites of glycosylation, two of which are in 
positions 30 and 80). Adapted from Lin F-K et al. Proc 
Natl Acad Sci USA. 1985; 82: 7580-7584 and Elliot S. et 
al. Nature Biotechnol. 2003; 21: 414-421. 
 
Erythropoietins of the first generation, 
recombinant human erythropoietin (rHu-EPO) alpha 
and beta, were identical to native erythropoietin 
(EPO) in their chemical structure and represented 
glycoproteid with molecular weight 30.4 kDa. The 
structure of an EPO molecule includes a single 
polypeptide chain comprising 165 aminoacids that is 
subjected to glycosylation with complementation of 4 
complex N-linked hydrocarbon chains (replacement 
of 3 asparaginic and 1 serine regions); they have 
several anionic free sialic acid residues determining 
EPO activity. It appears that not a single 
homogeneous molecule but a mixture of various 
isoforms specified on the number of free sialic acid 
residues is developed. This is associated with the fact 
that glycosylation of rHu-EPO is a posttranscriptional 
process and is not under the same strict genetic 
control as rHu-EPO mRNA translation. N-linked 
carbon side-chains pre-synthesize with various 
enzymes and are available for post-translational 
complementation to polypeptide rHu-EPO. Each 
isoform has its own bioactivity. Isoform 14 has the 
most erythropoietic activity. On the other hand, 
isoforms with the less number of sialic acid residues 
has more EPO receptor (EPOR) affinity, but a shorter 
period of circulation. Purified alpha and beta EPO 
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consist of a mixture of isoforms from 9 to 14. Alpha 
and beta erythropoietins have a relatively short half-
life period that necessitates their introduction into the 
correction phase as often as 3 times a week, and 
subcutaneous introduction once a week is allowed 
only in the maintenance phase of treatment [6, 7]. 
It is not unexpected that for a long time efforts 
of clinicians and pharmacologists were aimed at the 
development of preparations of the new generation 
with a longer half-life period; that would allow 
application of more convenient schemes of their 
introduction (once a week and even once in two 
weeks). A usual strategy of inhibiting rate of 
elimination of biomolecules lies in their pegylation, 
dimerization or synthesis of protein and polypeptide 
elements [8, 9].  
When creating darbepoetin there was applied a 
novel approach generally aimed at the increase of 
activity and reduce of clearance including directed re-
glycosylation-attachment of 2 complementary N-
linked hydrocarbon regions with active sialic residues 
to a base EPO molecule, so termed 
“glycoengineering”, or site-directed mutagenesis. As 
a result there was developed a principally new 
darbepoetin alpha molecule with a weight up to 37.1 
kDa having 5 glycosylation regions, and a number of 
free sialic groups were adjusted to 22. Darbepoetin 
alpha has less receptor affinity than EPO alpha and 
beta that is outweighed by the significantly bigger 
activity and long half-life period. As EPO alpha and 
beta preparations darbepoetin is produced by ovarian 
cells of the Chinese hamster subjected to the 
incorporation of a darbepoetin gene. Amino acid 
sequence of darbepoetin differs from that of human 
EPO in 5 positions, the fact that allows attaching 
complementary hydrocarbon branches to asparaginic 
residues in positions 30 and 88 without the 
destruction of total molecule conformation. Thus, 
darbepoetin differs from EPO by the high content of 
carbons and sialic residues, higher molecular weight 
and an increased negative charge [5, 10, 11]. 
  
 
 3 N-linked hydrocarbon chains                              
 Up to 14 sialic acid residues                        
 30.400 daltons            
 Hydrocarbon content up to 40%                             
 
 5 N-linked carbon chains 
 up to 22 sialic acid residues 
 37.100 daltons 
 hydrocarbon content up to 52 
 
Figure 2. Comparing structures of darbepoetin alpha (on the right) and rHuEPO (on the left) molecules. Arrows show 2 
complementary tetra-antenna N-linked carbon chains that led to more erythropoietic activity of darbepoetin due to 
prolongation of half-life period (explanations are given in the text). Adapted from Sinclair AM, Elliot S, 2005 
 
This provides proliferation, differentiation and 
survival of cells of erythroid lineage. In spite of the 
decreased receptor affinity darbepoetin has bigger 
biological activity and approximately tripled half-life 
period than EPO alpha [5, 12].                                                   
As stated above, darbepoetin has a prolonged period 
of half-life and inhibited clearance comparing to 
rHuEPO. Exact mechanisms explaining inhibited 
clearance of darbepoetin alpha and its metabolism are 
not completely investigated. Decreased EPO level in 
blood is described by a double decaying exponential; 
the first phase of rapid decrease may be conditioned 
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by binding with endothelial and erythroid cells. 
When liver, kidneys and bone marrow are considered 
as possible sites of EPO and darbepoetin degradation, 
the primary element of its metabolism is 
erythropoietic tissue through the mechanism of EPO-
receptor-inducible uptake. In this case difference 
between rapid elimination of de-sialylated EPO and 
inhibited clearance of darbepoetin is caused by the 
difference in EPO-receptor affinity [13]. 
  
Table 1 
Comparative characteristic of  rHuEPO alpha and beta and darbepoetin alpha (adapted from Deicher R, 
 Horl WH, 2004) 
 
 Epoetin-α Epoetin-β Darbepoetin-α 
Hydrocarbons content, % 40 40 52 
Number of N-linked carbon chains 3 3 5 
Half-life period, hours:intravenously,  
subcutaneously 
4-11 
19-25,3 
8,8-10,4 
24 
18-25,3 
48,8 
Bioavailability 
(subcutaneously), % 
30-36 15-50 37 
Clearance  (intravenously), 
ml/hour × kg 
8,1-8,6 7,9 2,0 
Frequency of introduction 
(number of times a week) 
1-3 0,5-3 0,25-1 
 
Table 2 
Application of erythropoietin and its analogues in various models of the brain damage. 
 
Author and 
date of pub-
lication 
Medici-
nal 
product 
Refer-
ence 
me-
dicinal 
product 
Model of stroke 
Method, dosage and 
time of introduction 
of medicinal product 
Research results 
1 2 3 4 5 6 
Ludmila 
Belayeva; 
Larissa 
Khoutorova
; 
Weizhao 
Zhao; 
Alexey 
Vigdorchik; 
Andrey 
Belayev; 
Raul Busto; 
Ella Magal; 
Myron D. 
Ginsberg 
2006 [14] 
Dar-
bepoetin 
alpha 
Human 
serum 
albumin 
Right middle 
cerebral artery 
occlusion was 
performed by 
ligation of this 
vessel during 
two hours; the 
method of in-
traluminal in-
troduction of 
poly-L-lysin 
coated suture 
was used. Su-
ture material 
was introduced 
retrogradely into 
the right exter-
nal carotid ar-
tery, then into 
the internal ca-
rotid artery and 
middle cerebral 
artery at the 
distance of 20-
22 mm from 
bifurcation. 
Darbepoetin alpha 
dosed 10mkg/ kg 
was introduced 
intraperitoneally at 
the moment of re-
perfusion, i.e. in two 
hours after the onset 
of middle cerebral 
artery occlusion.  
Human serum 
albumin (0.25%) 
10mkg/ kg 
Animals were divided into four groups: 
1. three-days survival value 
(darbepoetin alpha n=8) 
2. three-days survival value 
(reference medicinal product n=6) 
3. two-weeks survival value 
(darbepoetin alpha n=8) 
4. two-weeks survival value 
(reference medicinal product n=6) 
Neurologically significant improvement 
was in animals receiving reference 
medicinal products during the first hour 
after re-perfusion. 
Histologically areas of cerebral ischemia 
were significantly less in animals 
receiving darbepoetin comparing to 
animals receiving reference medicinal 
products: 
 In group 3 (two-weeks survival value) 
– 28,5±14,1 against 68,0±4,5 mm3  
 In group 1 (three-days survival value) 
– 28,9±5,3 against 46,4±5,3 mm3  
At that no significant difference in 
animals between groups were registered. 
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Table 2 (continued) 
1 2 3 4 5 6 
Wang Y.; 
Zhang 
Z.G.; 
Rhodes K.; 
Renzi M.; 
Zhang R.L.; 
Kapke A.; 
Lu M.; 
Pool C.; 
Heavner G.; 
Chopp M. 
2007 [15] 
Recom-
binant 
human 
erythro-
poietin 
Car-
bamylat
ed re-
com-
binant 
human 
eryth-
ropoi-
etin 
Middle cerebral 
artery occlusion 
was performed 
by vessels em-
bolization. 
Recombinant human 
erythropoietin was 
introduced in doses 
500; 1150 and 
5000IU/ kg
2
 in 6, 24 
and 48 hours after 
middle cerebral 
artery occlusion.   
Carbamylated 
recombinant human 
erythropoietin was 
introduced in doses 
50 mkg/ kg
2
 in 6, 24 
and 48 hours after 
middle cerebral 
artery occlusion.   
Neurological status of the studied animals 
was evaluated on the 7
th
, 14
th
, 21
st
 and 28
th
 
days. Histological examination of the brain 
was performed in 28 days. Neurological 
status carbamylated recombinant human 
erythropoietin was introduced in doses 50 
mkg/ kg
2
 of animals receiving for 28 days 
was better comparing to the group of 
animals receiving recombinant human 
erythropoietin was introduced in doses 500; 
1150 and 5000IU/ kg
2
. Histologically the 
size of ischemia in the cortical area was less 
in animals receiving recombinant human 
erythropoietin in doses 500; 1150 and 
5000IU/ kg
2
 or carbamylated recombinant 
human erythropoietin in doses 50 mkg/ kg
2 
(26% and 30% for recombinant human 
erythropoietin in doses 500; 1150 and 
5000IU/ kg
2 
respectively, and 36% for 
carbamylated recombinant human 
erythropoietin in doses 50 mkg/ kg
2
). 
recombinant human erythropoietin in a dose 
5000IU/ kg
2
 significantly decreases 
ischemia area not only in cortical, but also 
in sub-cortical layer by 22% and 36% 
respectively. 
Chrystal D 
Price; 
Zhongjin 
Yang; 
Rachel 
Karlnoski; 
Dipak Ku-
mar; 
Raphael 
Chaparro; 
Enric M 
Gampores 
2009 [16] 
Asi-
aloeryth
ropoi-
etin 
Physi-
ological 
saline 
solution 
Middle cerebral 
artery occlusion 
was performed 
by vessels em-
bolization. 
Rats from the experi-
mental group were 
introduced 
asialoerythropoietin 
in a dose 20 mkg/ kg, 
1 mcl/ hour for 24 
hours.   
Rats from the group 
of comparison were 
given physiological 
saline solution in a 
dose 1 mcl/ hour for 
4 days.   
The size of cerebral ischemia was assessed 
by the amount of apoptotic cells and 
concentration of activated caspase-3 and 9 
in the area of penumbra on the 4
th
 day. 
The size of ischemia significantly 
decreased in rats of the experimental 
group comparing to rats from the group of 
comparison (168±19 mm3 against 249±28 
mm
3
), the amount of apoptotic cells and 
concentration of activated caspase-3 and 9 
was also significantly less in the 
experimental group. 
Reitmeir 
R.; 
Kilic E.; 
Kilic U.; 
Bacigaluppi 
M.; 
El Ali A.; 
Salani G.; 
Pluchino S.; 
Gassmann 
M.; 
Hermann 
D.M. 
Recom-
binant 
human 
erythro-
poietin 
Physi-
ological 
saline 
solution 
Middle cerebral 
artery occlusion 
was performed 
by vessels em-
bolization. 
The animals of the 
experimental group 
were dosed recombi-
nant human erythro-
poietin through a 
catheter to the left 
lateral ventricle of 
the brain in doses 1 
IU/ day and 10 IU/ 
day; the medication 
was diluted with 
0.9% solution of 
NaCl in the volume  
Functional neurological tests performed 
on the 3
rd
, 14
th
 and 42
nd
 days after middle 
cerebral artery occlusion demonstrated 
significant improvement of motor abilities 
and coordination on the 14
th
 and 42
nd
 days 
after ischemia in the animals receiving 10 
IU of recombinant human erythropoietin a 
day. Immuno-histochemical examination 
performed on the 14
th
, 30
th
 and 52
nd
 days 
after ischemia allowed concluding that a 
high dose of recombinant human 
erythropoietin increased neurons 
“survival value” on the 52nd day of  
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Table 2 (continued) 
1 2 3 4 5 6 
2010 [16].    of infusion 0.25 
mcL/ hour. The 
correctness of 
ischemia modeling 
was assessed by the 
Doppler sonography 
examination. 
examination, decreased progressive 
cerebral atrophy having no affect on the 
callosal thickness, reduced diffuse 
astrocytosis and glial scars formation. De-
creased level of inflammatory markers  
(IL-1β, IL-6, leukolysis inhibiting factor, 
transforming growth factor, tumor 
necrosis factor, glial fibrillary acid 
protein) in animals receiving  10 IU of 
recombinant human erythropoietin per 
day, which were examined on the 3
rd
, 14
th
 
and 30
th
 day after ischemia, also 
supported positive impact of high doses of  
recombinant human erythropoietin. 
Marcus 
Mazur; 
Robert H.; 
Miller 
Shenandoah 
Robinson 
2010 [17] 
Erythro-
poietin  
Physi-
ological 
saline 
solution 
Uterine artery 
occlusion during 
60 min. on the 
18
th
 day of em-
bryogenesis (in-
fant rats were 
born at term, i.e. 
on the 22
nd
 day 
of the embryo-
nal develop-
ment). 
Recombinant human 
erythropoietin was 
introduced 
intraperitoneally 
starting with the 1
st
 
day of post-natal 
period. Animals of 
group 1 were intro-
duced 500 IU/kg a 
day. Animals of 
group 2 were 
introduced 1000 
IU/kg a day for 3 
days. Animals of 
group 3 were intro-
duced 2000 IU/kg a 
day for 5 days.  
Immuno-histological examination was 
performed on the 2
nd
, 5
th
 and 9
th
 days after 
the birth. During 2 weeks after 
intrauterine ischemia there was increased 
activity of caspase-3 and increased 
amount of apoptotic cells in the animals 
receiving erythropoietin in a dose 1000 
IU/kg a day for 3 days. Significantly less 
amount of immune-positive 
oligodendrocytes was found in alba of the 
animals receiving physiological saline 
solution in contrast to the animals 
receiving erythropoietin in any dosage. 
Physiological tests showed that animals 
receiving 2000 IU/kg a day for 5 days did 
the tasks better comparing to animals 
from other groups.  
Lella 
Cherian; 
J. Clay 
Goodman; 
Claudia 
Robertson 
2011 [18] 
Dar-
bepoetin 
alpha 
Physi-
ological 
saline 
solution 
Brain trauma 
was performed 
using a crani-
otome 8 mm in 
diametre, which 
was introduced 
into the right 
area of the skull 
above the pari-
etal bone. Then 
the injury in the 
form of 8 mm 
hole was per-
formed in a 
certain position 
using a “striking 
tool” and a stem 
was introduced 
through this 
hole;  then 3 
mm deformation  
Darbepoetin was in-
troduced by 2.5; 5; 
10; 25 and 50 
mkg/kg 
subcutaneously in 5 
min., 1 hour, 3 hours, 
6 hours, 9 hours 12 
hours and 24 hours 
after the trauma. 
Histological examination of the size of the 
brain damage showed significant effect of 
the darbepoetin therapy in doses 25 and 
50 mkg/kg  5 min after brain trauma 
(8.1±3.1 and 11.1±6 mm3, respectively), 
than in animals treated with physiological 
saline solution (39.1±6.7 mm). 
There was also significant effect 
depending on the time of preparation 
introduction: 
 When injecting 25 mkg.kg of 
darbepoetin the size of the 
damaged area reduced up to 
10.5±5 mm3 when introduced 
after 5 min after trauma; 
 When introduced in 1 hour – up 
to 9.2±3.6 mm3; 
 When introduced in 3 hours – up 
to11.3±2.4 mm3; 
 When introduced in 6 hours – up 
to 14.7±4.4 mm3 
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Table 2 (continued) 
1 2 3 4 5 6 
   of the brain was 
done using this 
stem. 
 The size of the damaged area amounted to 
42.9±11mm3 in the animals that were 
applied physiological saline solution. 
 
Elizarova 
O.S.; 
Balaban'ya
n V.YU.; 
SHipulo 
E.V.; 
Maksi-
menko 
O.O.; 
Vanchugo-
va L.V.; 
Litvino-va 
S.A.; 
Garibova 
T.L.; 
Voronina 
T.A.; 
Gel'pe-rina 
S.E. 
2012 [19] 
Nano-
somal 
form of 
low co-
sial-
yated 
recom-
binant 
human 
erythro-
poietin 
on the 
basis of 
nano-
particles 
from 
polylac-
tic-co-
glycolic 
acid 
stabi-
lized by 
1% hu-
man 
serum 
albu-
min. 
Native 
low co-
sial-
yated 
recom-
binant 
human 
eryth-
ropoi-
etin 
(OOO 
“Protei-
novy 
kontur”, 
Russia) 
Localized brain 
hemorrhage 
(auto-hemor-
rhagic left brain 
stroke) was 
simulated in the 
area of internal 
capsule (capsule 
interna, coordi-
nates H=5mm, 
L=3.5 mm, A=2 
mm from 
bregma) 
Nanosomal form of 
low co-sialyated re-
combinant human 
erythropoietin and 
native low co-
sialyated 
recombinant human 
erythropoietin were 
injected 
intravenously in a 
dose 0.05 mg/kg; 
prior to injecting na-
noparticles 
preparation was 
diluted in 1% so-
lution of Pluronic 
F68. The first 
introduction was 
performed in 3-3.5 
hours after the 
operation and 
recovery of an ani-
mal after narcosis. 
The repeated 
application was 
performed on the 
second and third 
days after the 
operation. False-
operated rats and rats 
from the control 
group with hem-
orrhagic stroke were 
introduced 
physiological saline 
solution according to 
the same scheme. 
Dynamics of intracerebral post-traumatic 
hematoma development was studied on 
the 1st, 3rd and 7th day with death 
registration. Study of survival dynamics 
in rats showed that up to the 7th day of 
observation all false-operated rats 
survived; in the group of animals with 
intracerebral post-traumatic hematoma the 
survival value amounted to 40%.  
On the background of the repeated 3-days 
injection of low co-sialyated recombinant 
human erythropoietin incorporated into 
nano-particles from polylactic-co-glycolic 
acid, the survival value in rats was 77.8% 
till the end of the experiment; this was 
40% more than in rats of the control 
group with intracerebral post-traumatic 
hematoma.  
 Native low co-sialyated recombinant 
human erythropoietin did not practically 
influence the survival value in rats with 
intracerebral post-traumatic hematoma; 
this fact might indirectly prove 
insufficient dose of the introduced 
preparation for producing therapeutical 
concentration in the brain and neuro-
protective effect. 
Alexander 
M.L.; 
Hill C.A.; 
Rosenkrant
z T.S.; 
Fitch R.H. 
2012 [1] 
Erythro-
poietin  
Physi-
ological 
saline 
solution 
Ligation of the 
right common 
carotid artery 
for two hours; 
after that – two 
hours hypoxia 
under humidi-
fied 8% oxygen 
and 92% nitro-
gen. 
Animals were 
divided into 2 groups 
and 6 sub-groups: 
Animals of the group 
1a were introduced 
1000 IU/kg of eryth-
ropoietin right after 
ischemia;  
animals of the group 
1b were introduced 
1000 IU/kg of  
Statistical analysis of behavioral tests and 
histological examination was performed 
using dispersion method. Current study 
showed that there was practically no ther-
apeutical effect on the introduction of 
erythropoietin in 60 or 180 min. after 
ischemia. Assessment of the ventricular 
pathology revealed the fact that 
significant swelling of the brain ventricles 
on the right was registered in the group of 
animals receiving physiological saline  
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Table 2 (continued) 
1 2 3 4 5 6 
    erythropoietin in 60 
min. after ischemia; 
animals of the group 
1c were introduced 
1000 IU/kg of eryth-
ropoietin in 180 min. 
after ischemia; 
animals of the 
groups 2a, b and c 
were introduced 
physiological saline 
solution in volumes 
and with time 
intervals equivalent 
to each of sub-
groups receiving 
erythropoietin. 
 
solution, and also in animals that were 
injected erythropoietin in 180 min. after 
ischemia comparing to the other groups of 
animals that did not manifested apparent 
ventricular pathology.  
In both – animals receiving erythropoietin 
in 60 and 180 min. after ischemia and in 
animals receiving physiological saline 
solution the amount of apoptotic cells and 
the size of ischemia histologically 
significantly increased. There was also 
histologically proved therapeutical effect 
of erythropoietin in animals receiving 
erythropoietin right after ischemia. Thus, 
the study supported the inefficiency of the 
delayed introduction of erythropoietin. 
Carin 
Sjolund; 
John-Kalle 
Lansberg; 
Tadeusz 
Wieloch; 
Karsten Ru-
scher; 
Bertil Rom-
ner 
2013 [20] 
Erythro-
poietin 
Physi-
ological 
saline 
solution 
Two vessels ten 
minute ligation 
with suture ma-
terials (right and 
left carotid ar-
teries) 
Animals of the first 
group were single-
dosed 80 IU of eryth-
ropoietin multiplied 
by the volume of 
distribution (VD; 
0.057 ml/g BW), 
intravenously 
(Neorecormon 
Roshe, Switzeland) 
right after the 
operation; 160 
IU/hour in 
succeeding 72 hours. 
Animals of the 
second group were 
introduced 
physiological saline 
solution according to 
the same scheme. 
Examination of sensor-motor functions 
and memory tests performed on the 3
rd
 
day of the experiment showed that the 
group of animals receiving erythropoietin  
did tasks better than the group of animals 
receiving physiological saline solution. 
Neuro-protective effect of erythropoietin 
was also determined by the histological 
examination of the brain in which neurons 
of the control animals were specified as 
big violet cells 30-50 mm in diametre 
with a large sub-circular nucleus; 
damaged neurons were specified as red-
rosy patches triangle in form with a 
shrunken dark nucleus. In general histo-
logical examination did not reveal 
significant changes in the brain of the 
animals receiving erythropoietin as well 
as in animals receiving physiological sa-
line solution. The results of the 
experiment demonstrated that treatment 
with erythropoietin did not affect the 
amount of apoptotic cells, did not protect 
from the ischemic damage, but preserved 
synaptic membrane function; behavioral 
tests and memory tests proved this.  
Sheng-Kai 
Wu; 
Ming-Tao 
Yang; 
Kai-Hsiang 
Kang; 
Houng-Chi 
Liou; 
Recom-
binant 
erythro-
poietin 
(Merck 
KGa, 
Darm-
stadt,  
-  Three vessels 
ligation with 
suture materials 
(right and left 
carotid arteries, 
middle cerebral 
artery) 
In the study animals 
were divided into 
groups depending on 
the way of the prepa-
ration introduction: 
Group A (control) – 
50 min. ischemia; 
Group B – 50 min.  
Histological picture of the brain showed 
significant decrease of the brain ischemia 
size in animals receiving erythropoietin 
using phonophoresis. Neurological status 
examination was performed in 24 hours 
after ischemic reperfusion and it was 
registered that therapy with the help of 
phonophoresis significantly improved  
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1 2 3 4 5 6 
Dai-Hua 
Lu; 
Wen-Mei 
Fu; 
Win-Li Lin 
2014 [21] 
Ger-
many) 
-   ischemia, animals 
were twice 
introduced 5000 
IU/kg of recom-
binant erythropoietin  
in 5 hours after re-
perfusion using 
phonophoresis; 
Group C – 50 min. 
ischemia,  animals 
were single-dosed in-
travenously 5000 
IU/kg of 
recombinant 
erythropoietin  in 5 
hours after re-perfu-
sion; 
Group D – 50 min. 
ischemia, animals 
were single-dosed in-
travenously 5000 
IU/kg of 
recombinant 
erythropoietin  in 5 
hours after re-perfu-
sion using 
phonophoresis. 
neurological functions and reduced 
neurological assessment scores.  
Immuno-histochemical staining of the 
brain performed in 24 hours after 
ischemia/ reperfusion showed evident 
neuron death in groups A and C, while in 
groups B and D phonophoresis had fa-
vourable effect on the neurons “survival 
value’. Thus, the authors concluded that 
introduction of recombinant 
erythropoietin using phonophoresis 
increased penetration of the brain vessels 
and improved neuroprotective effect of 
this preparation. 
Haiping 
Zhao; 
Rongliang 
Wang; 
Xiaoning 
Wu; 
Jia Liang; 
Zhifeng Qi; 
Xiangrong 
Liu; 
Lianqui 
Min; 
Xunming 
Ji; 
Yumin Luo 
2015 [21] 
Erythro-
poietin  
-  Occlusion of the 
middle cerebral 
artery was per-
formed for 2 
hours by 
embolization of 
vessels followed 
by 24 hours 
reperfusion. 
Animals of the first 
group were 
introduced 800 IU of 
erythropoietin per kg 
in the middle 
cerebral artery in-
travascularly. 
Animals of the 
second group were 
introduced 5000 IU 
of erythropoietin per 
kg subcutaneously. 
Neurobehavioral deficiency and the brain 
ischemia size was less in the animals 
receiving 800 IU of erythropoietin per kg 
in the middle cerebral artery intravas-
cularly. Erythropoietin also suppressed 
expression of stress glucose dependant 
protein 78 of the endoplasmatic reticulum, 
activation of the tumor necrosis factor and 
reduced level of pro-apoptotic caspase-3 
in micro-vessels of the brain in these 
animals. Research results support 
neuroprotective effect of low doses of 
erythropoietin (800 IU/kg) when 
introducing intravascularly in the middle 
cerebral artery after experimental acute 
ischemic brain damage. 
 
Results. As the given Table shows, the most 
popular model of stroke is considered to be two- 
or three vessels ligation of arteries; simulation of 
occlusion of uterine arteries was used for the 
study of erythropoietin effect on the treatment of 
intra-uterine fetal hypoxia. The attention should 
be also paid at the interesting and technically 
complicated method of localized brain 
hemorrhage (auto-hemorrhagic left brain stroke) 
in the area of the internal capsule. All the 
researchers tended to compare low- and high dose 
effect of erythropoietin and its analogues and to 
study their effect in various dosages and using 
various methods of introduction. The most 
popular method of assessment of research results 
was histological validation of ischemia and 
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assessment of neurological status performing 
various static and dynamic tests. When 
summarizing all the research results it is evident 
that neurological symptoms in the animals 
receiving high doses of erythropoietin and its 
analogues, especially during the first hours after 
damage, improved significantly; neurobehavioral 
deficiency reduced; functions of the limbs and 
memory functions recovered significantly more 
rapidly; inefficiency of the delayed introduction 
of erythropoietin and its derivatives was also 
registered. The brain ischemia size and the 
amount of apoptotic cells histologically reduced, 
concentration levels of inflammatory markers 
reduced. Analyzing the data obtained the authors 
may conclude that ways of introduction do not 
affect the outcome of the studied preparations. 
Conclusions. The results of the analysis performed 
support efficiency of application of erythropoietin in 
various forms, as well as its genetically-modified 
analogue – darbepoetin. It has been demonstrated in 
vitro and in vivo that erythropoietin is considered to be 
a strong inhibitor of neuron apoptosis induced by 
ischemia and oxygen deficiency. However, 
erythropoietin blood-forming activity has unfavourable 
side effect – increased arterial pressure and risk of blood 
clot formation – that is, in case of ischemic stroke, 
strongly counter-indicative even if erythropoietin is 
applied for a very short period. Related to this fact there 
are known attempts to develop modified erythropoietin 
having no blood-forming activity but preserving 
cytoprotective properties. One of such modified 
erythropoietin variants is reported to be its de-sialyated 
form, which has high affinity to classical forms of 
erythropoietin receptors, but fails to reveal blood-
forming activity in vivo due to short half-life period in 
blood plasma. Another variant of modified 
erythropoietin represents carbamylated erythropoietin. 
Protein carbamylation is widely known to be a side-
effect of urea application in purification of proteins and 
as a result of high urea level in the serum. In such cases 
carbamylation results from urea decomposition into 
cyanates. Cyanate is responsible for carbamylation of 
the primary amines of protein in the N-terminal end and 
amino acid residues of lytic protein subjected to 
carbamylation. Other amino acid residues possibly 
subjected to carbamylation are argentine, cysteine, 
tyrosine, aspartic acid, glutaminic acid, histidine; 
however, the reaction depends on pH and does not go as 
rapidly as with the N-terminal end and amino acid 
residues of lytic protein. Carbamylation of 
erythropoietin on 7 available lysine residues replaces 
them on the residues of homocitrullin not involving the 
profile of glycosylation of the entire molecule. It is 
demonstrated that carbamylated erythropoietin does not 
interact with classical erythropoietin receptors but 
preserves cytoprotective properties. The major 
advantage of carbamylated erythropoietin comparing to 
de-sialyated form of erythropoietin lies in the fact that 
carbamylation in contrast to de-sialyation does not 
significantly change kinetic profile. Half-life period of 
carbamylated erythropoietin in the blood plasma, as is 
has been showed in rats, is the same as of erythropoietin 
– 3 – 6 hours; this is caused by preservation of sialic 
acid residues. Darbepoetin is reported to be genetically-
modified erythropoietin and has all properties of the 
natural analogue. Comparing to standard erythropoietin 
darbepoetin has bigger molecular weight (37.1 kDa and 
not 30.4 kDa) and maximally possible amount of sialic 
acid residues (22 against 14 in erythropoietin) due to 
introduction of 2 complementary sites of glycosylation. 
This results in the increase of half-life elimination 
period and, consequently, reduces the application 
frequency of the preparation [5, 23]. There exists one 
more form of darbepoetin containing carbamylated 
groups of all eight amino acid residues of lysine 
included in a darbepoetin molecule and carbamylated 
amino acid residue of alanine in the N-terminal end of 
this protein – carbamylated darbepoetin, which does not 
affect hemopoetic activity but preserves cytoprotective 
properties. Carbamylated darbepoetin has more 
prolonged half-life period comparing to Carbamylated 
erythropoietin and, consequently, and may be 
prospective when applying in vivo as a cytoprotective 
medicinal product in case of disorders resulting in cell 
death due to hypoxia. There is lack of information in 
literature about the effect of this substance as a 
medication with cytoprotective action, and the number 
of investigational pre-clinical trials is not sufficient; this 
may become a pre-requisite to new research studies. 
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